Ginkgo Bioworks is making strong progress in cost management and achieving technical milestones with major customers, despite facing challenges in revenue from cell engineering and biosecurity. The company maintains a robust cash position and is ahead of schedule in cost-cutting targets. However, declines in certain revenue streams and the impact of one-off costs on cash burn present challenges. Overall, the company is on a positive trajectory towards breakeven.

Company Guidance

In the Q3 2024 earnings call for Ginkgo Bioworks, the company provided guidance indicating a strong focus on achieving adjusted EBITDA breakeven while maintaining a robust cash margin of safety. As of the end of the quarter, Ginkgo reported $616 million in cash with no bank debt, having exceeded their cost-cutting target for 2024, achieving a $125 million annualized run rate cash OpEx improvement relative to Q1. The company updated its total revenue guidance for the year to be between $215 million and $235 million, with Cell Engineering services revenue projected at $165 million to $185 million, and Biosecurity revenue remaining at a minimum of $50 million. Ginkgo also highlighted significant strides in their customer engagements, achieving a $9 million technical milestone with Merck, and expanding their offerings with new data points business and Biosecurity services addressing H5N1. Despite the cost-cutting initiatives, Ginkgo emphasized continued service to current customers and the acquisition of new ones, setting a path towards breakeven by mid-2026.

Exceeded Cost-Cutting Targets

Ginkgo Bioworks has surpassed its cost-cutting target for 2024, achieving a $125 million annualized run rate cash OpEx improvement relative to Q1.

Cash Position and Debt Management

The company ended the quarter with $616 million in cash and no bank debt, maintaining a strong cash margin of safety.

Significant Improvement in Adjusted EBITDA

Adjusted EBITDA improved to negative $20 million, a significant enhancement from negative $84 million in Q3 2023.

New Customer Wins and Revenue Growth

Ginkgo announced a $9 million milestone with Merck and signed deals with new top 25 biopharma for its data points products.

Growth in Active Programs

The company supported 136 active programs across 81 customers, marking a 17% increase year-over-year.

---

Ginkgo Bioworks Holdings (DNA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

DNA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Feb 27, 2025	2024 (Q4)	-1.50 / -	-4.4	―	―	―
Nov 12, 2024	2024 (Q3)	-2.73 / -1.08	-6.4	83.13% (+5.32)
Aug 08, 2024	2024 (Q2)	-3.10 / -4.40	-3.6	-22.22% (-0.80)
May 09, 2024	2024 (Q1)	-3.33 / -3.20	-4.4	27.27% (+1.20)
Feb 29, 2024	2023 (Q4)	-3.87 / -4.40	-4	-10.00% (-0.40)
Nov 08, 2023	2023 (Q3)	-3.66 / -6.40	-16.4	60.98% (+10.00)
Aug 09, 2023	2023 (Q2)	-3.45 / -3.60	-16.4	78.05% (+12.80)
May 10, 2023	2023 (Q1)	-3.40 / -4.40	-14.8	70.27% (+10.40)
Mar 01, 2023	2022 (Q4)	-8.32 / -4.00	-44	90.91% (+40.00)
Nov 14, 2022	2022 (Q3)	-10.47 / -16.40	-3.2	-412.50% (-13.20)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

DNA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 12, 2024	$8.39	$8.60	+2.50%
Aug 08, 2024	$11.43	$10.81	-5.42%
May 09, 2024	$36.80	$30.44	-17.28%
Feb 29, 2024	$60.80	$51.60	-15.13%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---